RSC Advances



View Article Online

View Journal | View Issue

PAPER

Check for updates

Cite this: RSC Adv., 2022, 12, 2574

Received 13th July 2021 Accepted 15th December 2021

DOI: 10.1039/d1ra05382e

rsc.li/rsc-advances

1. Introduction

Cancer is the one of the most devastating diseases to human health and a leading cause of death worldwide. In the past few years, a number of chemotherapeutic drugs such as doxorubicin (DOX), curcumin, quercetin (QSR), camptothecin, etc. have been widely employed for the treatment of various kinds of cancer. Besides having numerous advantages, these drugs also exhibit a number of serious drawbacks such as nonspecific distribution, inadequate drug concentrations in cancerous cells, overdose, short distribution period and low bioavailability as well as severe toxicity to healthy cells.^{1,2} Furthermore, it is well known that most of the anticancer drugs, due to their hydrophobic nature, are insoluble or sparingly soluble in aqueous and physiological solution. Particularly, a well-known drug quercetin (QSR), 3,3',4',5',7pentahydroxyflavone belongs to the class of flavonoids that possess anticancer activity as well as a wide variety of

Polymer grafted magnetic graphene oxide as a potential nanocarrier for pH-responsive delivery of sparingly soluble quercetin against breast cancer cells

Monika Matiyani,^a Anita Rana,^a Mintu Pal,^b Sravendra Rana,^b Anand B. Melkani^a and Nanda Gopal Sahoo^b *^a

In this work, polymer grafted magnetic graphene oxide (GO–PVP–Fe₃O₄) was successfully synthesized for efficient delivery of anticancer drug. Firstly, GO was functionalized with the hydrophilic and biocompatible polymer polyvinylpyrrolidone (PVP) and then grafted with magnetic nanoparticles (Fe₃O₄) through an easy and effective chemical co-precipitation method. Quercetin (QSR) as an anticancer drug was loaded onto the surface of GO–PVP–Fe₃O₄ *via* non-covalent interactions. The drug loading capacity was as high as 1.69 mg mg⁻¹ and the synthesized magnetic nanocarrier shows pH-responsive controlled release of QSR. The cellular cytotoxicity of the synthesized nanocarrier with and without drugs was investigated in human breast cancer MDA MB 231 cells and their effects compared on non-tumorigenic epithelial HEK 293T cells. These results reveal that the drug loaded GO–PVP–Fe₃O₄ nanohybrid was found to be more toxic than the free drug towards MDA MB 231 cells and exhibits biocompatibility towards HEK 293T cells. Overall, a smart drug delivery system including polymer grafted magnetic graphene oxide as a pH-responsive potential nanocarrier could be beneficial for targeted drug delivery, controlled by an external magnetic field as an advancement in chemotherapy against cancer.

pharmacological and biological properties.³⁻⁵ However, QSR has suffer from low bioavailability due to its limited aqueous solubility which limits its biological applications.⁶ To suppress the above limitation of the drug, there is a need for an effective drug carrier which can increase the solubility of the drug in aqueous and physiological media as well as enhance drug efficacy and lower drug toxicity due to controlled drug release. In this regard, nanocarriers have been emerged as promising tools having excellent ability to deliver the drug at respective sites due to their nanosized structure and large surface area. There are a number of nanocarriers including dendrimers, liposomes, polymeric micelles, carbon nanomaterials, metal oxide nanoparticles, *etc.* which can effectively deliver the drug to the drug to the cancerous or tumor cells and show remarkable potential in the field of drug delivery.

Graphene, a two-dimensional mono-layer sheet of sp² hybridized carbon atoms, in which carbon atoms are arranged in honeycomb-like structure. Graphene has gained remarkable attention in the past few decades due to its extraordinary properties such as great mechanical strength, excellent chemical stability, large surface area and *etc.*⁷⁻¹⁰ Among various derivatives of graphene, graphene oxide (GO) has been extensively studied as one of the most promising drug carriers for effective drug delivery due to its distinctive chemical and

^eProf. Rajendra Singh Nanoscience and Nanotechnology Centre, Department of Chemistry, D. S. B. Campus, Kumaun University, Nainital-263001, Uttarakhand, India. E-mail: ngsahoo@yahoo.co.in

^bDepartment of Pharmacology, AIIMS, Bathinda, Punjab, India

^cUniversity of Petroleum & Energy Studies (UPES), School of Engineering, Department of Chemistry, Energy Acres, Bidholi, Dehradun 248007, India

Paper

physical characteristics. The presence of abundant hydrophilic oxidative functional groups on the surface of GO are responsible for its better dispersibility in water as well as in physiological solution. In addition, these oxygenated groups are capable to form covalent or non-covalent bonds with other functional moieties in order to modify the surface of GO.¹¹⁻¹³ GO has also shown excellent ability to load chemotherapeutic drugs and other chemical moieties through hydrogen bonding, electrostatic interactions and π - π interactions.^{14,15} Despite these, GO also suffer from its poor biocompatibility and exhibit lack of stability in physiological solution which restricts its application in drug delivery. To overcome these limitations, the surface modification of GO is enormously gaining interest in improving the potential of GO.16 The functionalized GO can also extend hydrophilicity to hydrophobic drugs and can be used as the efficient and effective nanocarrier for anticancer drug.17

In recent years, different hydrophilic and biocompatible polymers¹⁸⁻²³ have been used for the functionalization of GO which increases its biocompatibility, solubility and stability in biological solutions as well as improve the dissolution of waterinsoluble anticancer drugs. However, to enhance therapeutic efficiency of anticancer drug and induces targeting ability, GObased nanocarriers are incorporate with the magnetic nanoparticles.²⁴⁻²⁷ In magnetic nanoparticles, Fe₃O₄ nanoparticles have received much attention and also, most commonly used as a source of magnetic nanoparticles due to its unique features such as good biocompatibility, ease of preparation, high superparamagnetic character, low toxicity, excellent chemical stability.28,29 It is well known fact that GO and Fe₃O₄ nanoparticles are showed the agglomeration separately in the solution media. But, when these are come together, they showed the synergic effect towards each other, magnetic nanoparticles avoid the lapping of GO sheets and on the other hand, GO avoid the agglomeration of magnetic nanoparticles.³⁰ Yang et al. synthesized GO-Fe₃O₄ based nanocarrier for the loading of DOX and reported 1.08 mg mg⁻¹ DOX loading capacity.²⁷ On the other hand, Tiwari et al. prepared GO-PVP based nanocarrier for dual delivery of Gefitinib (GEF) and QSR. They found that the loading capacity of GO-PVP for GEF and QSR (single drug systems) are 20% and 14%, respectively, and GO-PVP-QSR-GEF (dual drug system) shows loading capacity of GEF and QSR are 46% and 20%, respectively.21

In the present work, we have successfully synthesized polyvinylpyrrolidone-grafted magnetic GO (GO–PVP–Fe₃O₄) as a nanocarrier for the loading and delivery of anticancer drug quercetin (QSR). The prepared nanocarrier shows the excellent loading capacity for the QSR of 1.69 mg mg⁻¹ which is higher in compared to the previously reported work in GO-based nanocarrier for several anticancer drugs. Also, it exhibits the pH-triggered release behavior for QSR. Further, QSR loaded GO–PVP–Fe₃O₄ nanocarrier has been investigated for cytotoxicity against non-tumorigenic HEK 293T and human breast cancer MDA MB 231 cells. QSR loaded GO–PVP–Fe₃O₄ nanocarrier stowards the MDA MB 231 breast cancer cell in comparison to the pure QSR; whereas no significant cytotoxic effects in the normal cells. Our novel

findings reveal that the synthesized magnetic nanocarrier could be a promising candidate for cancer therapy.

2. Experimental

2.1 Materials

Expanded graphite powder (average particle size ~100 μ m) and quercetin (QSR) were purchased from Sigma-Aldrich. Polyvinylpyrrolidone (PVP, $M_w \sim 40\,000$) was obtained from Calbiochem. Hydrogen peroxide (H₂O₂, 30 wt% aqueous solution), sodium nitrate (NaNO₃), sulphuric acid (H₂SO₄), potassium permanganate (KMnO₄), iron(II) sulfate heptahydrate (FeSO₄-·7H₂O), iron(III) chloride hexahydrate (FeCl₃·6H₂O), sodium hydroxide (NaOH), fetal bovine serum (FBS), penicillin–streptomycin, sulforhodamine B (SRB) assay and Eagle's minimum essential medium (MEM) with NEAA were obtained from Himedia. *N*,*N'*-dicyclohexyl carbodiimide (DCC) and 4-dimethylaminopyridine (DMAP) were obtained from Sisco Research Laboratories Pvt. Ltd (SRL).

2.2 Preparation of GO

GO was synthesized from expanded graphite powder using a modified Hummer's method.³¹ Briefly, 1 g of expanded graphite powder was mixed with 1 g of NaNO₃ and 46 mL of H₂SO₄ and stirred continuously for half an hour at 27 °C. After that, under ice-water bath condition, 6 g of KMnO₄ was added slowly to the obtained slurry mixture with stirring followed by heating at 32 °C for 2 hours. After vigorously stirring for 2 hours, 92 mL double distilled water (DD water) was added slowly to the solution mixture followed by maintaining the temperature at 95 °C with stirring over about 1 hour. The resultant mixture was further stirred for 2 hours after adding 200 mL of DD water. Later on, 30 mL of H₂O₂ (30 wt% aq.) was added to the mixture and continuously stirred at room temperature for 1 hour. Lastly, the oxidized product was purified with 10% HCl solution and repeatedly washing with DD water until the final product has been neutralized.

2.3 Preparation of PVP grafted GO (GO-PVP)

GO was functionalized with PVP through carbodiimide activated esterification method.^{32,33} In this method, firstly, GO solution was prepared by dissolving 50 mg of GO in 15 mL of DMSO and then the solution was sonicated for 45 min to obtain a brown-colored homogeneous solution. After that, a definite quantity of PVP heated for 15 min with small amount of dilute hydrochloric acid. Further, an appropriate quantity of catalysts DCC and DMAP were added gradually to the solution of PVP and continuously stirred for 30 min. Then, 15 mL of GO solution was added to the resulting mixture followed by stirring for three days at a heating temperature of 50 °C. After three days continuous stirring, the solution was filtered through a PTFE microporous membrane $(0.2 \ \mu m)$ and the resulting solid was washed with acetone and dimethylformamide (DMF). Then, the solid was dissolved in hot water followed by the filtration through 0.2 µm nylon membrane to remove unreacted PVP. Finally, the filtered residue was collected after washing with

RSC Advances

a significant amount of hot water and dried in a vacuum oven. The detailed mechanism of coupling between GO and PVP is shown in Scheme 1.

2.4 Preparation of Fe₃O₄ magnetic nanoparticles functionalized GO-PVP (GO-PVP-Fe₃O₄)

The functionalization of GO–PVP with Fe₃O₄ magnetic nanoparticles has been done by chemical co-precipitation method (Scheme 2).³⁴ In a typical procedure, 0.5 g of GO–PVP dispersed in 50 mL of DD water and sonicated for 30 min. The 100 mL solution containing 556 mg of FeSO₄·7H₂O and 1081 mg of FeCl₃-·6H₂O salts continuously stirred at 40 °C for about 30 min and thereafter reaction mixture was adjusted to pH 4 by the addition of 1 M NaOH solution. The next step was the addition of sonicated GO–PVP solution to the mixture of Fe(π)/Fe(π) followed by the stirring for 1 hour. Finally, 1 M NaOH solution was added to the resulting solution to reach pH 10 and then the solution was allowed to stand for 1 hour. Then, the resultant precipitate was separated with the help of magnet and repeatedly washed with DD water and subsequently, dried overnight in an oven at 50 $^\circ\mathrm{C}.$

2.5 Loading of QSR on GO-PVP-Fe₃O₄ composite

Briefly, 4 mL of 1 mg mL⁻¹ GO–PVP–Fe₃O₄ composite in phosphate buffer solution (PBS, pH 7.4) was mixed with 2 mL of 4 mg mL⁻¹ QSR solution in DMSO and then stirred for 24 hours at room temperature. The drug-loaded nanocarrier was then magnetically separated and washed 2–3 times with DD water. Finally, the purified drug-loaded nanocarrier dried in a vacuum oven at 40 °C.

2.6 In vitro drug release

To study drug release behavior, 10 mg of QSR loaded GO–PVP– Fe_3O_4 nanocarrier was added in a beaker and dispersed by adding 20 mL of pH 4 and 7.4 buffer solution separately. Then, beakers were placed in a shaker constantly for 3 days at room temperature. At definite time intervals, 3 mL supernatant



Scheme 1 Detailed mechanism of coupling between GO and PVP.



Scheme 2 Schematic representation of synthesis of magnetic graphene oxide and drug loading on magnetic graphene oxide.

solution was taken out from the beaker and replaced by equal volume of fresh buffer solution to keep a constant amount of solution in a beaker during the whole experiment. Finally, the collected supernatants were examined by UV-visible spectrophotometer to determine the amount of the drug released.

2.7 Fabrication of QSR, GO–PVP–Fe₃O₄ and GO–PVP–Fe₃O₄– QSR nanocomposite-modified electrode

The electrodes were prepared by drop-casting method as reported previously.³⁵ Briefly, 1 mg of QSR, GO–PVP–Fe₃O₄ and GO–PVP–Fe₃O₄–QSR were dispersed in 1 mL of DD water separately and sonicate for 1 hour to make a homogenous mixture. For the preparation of electrode, initially glassy carbon electrode (GCE) was polished with the alumina power, then 60 μ L of each QSR, GO–PVP–Fe₃O₄ and GO–PVP–Fe₃O₄–QSR were drop cast separately onto the surface of GCE and dried at 60 °C in the oven. After that, the prepared electrodes were immersed in 0.1 M PBS (pH 7.4) for electrochemical measurements in three electrode system with Pt wire and Ag/AgCl as the counter and reference electrodes, respectively. This study was done for the confirmation of QSR loading onto the GO–PVP–Fe₃O₄.

2.8 Cell culture and in vitro cytotoxicity assay

The human breast cancer MDA MB 231 cell line and nontumorigenic HEK 293T epithelial cell line were obtained from the National Center for Cell Sciences (NCCS), Pune, India. The cells were cultured and maintained by using a suitable culture medium containing 1% penicillin/streptomycin as an antibiotic and 10% fetal bovine serum (FBS) in a 5% CO₂ incubator at 37 °C in a humidified environment. As reported previously,³⁶ sulforhodamine B (SRB) assay was carried out to evaluate the relative cell survival percentage. Briefly, cells at a concentration of 3000 cells per well were seeded in 96 well microtiter plates and treated with various concentrations $(0, 10, 20, 30, and 50 \mu g$ mL^{-1}) of the synthesized nanocarriers (with and without drug). After the treatment of 48 hours, each well was filled with 25 μ L of cold 50% trichloroacetic acid (TCA) and the plates were incubated for 1 hour at 4 °C. To eliminate the serum proteins and TCA solution, the wells were rinsed with water and then, the plates were dried. Then, each well was filled with 50 µL of a 0.4% SRB solution and the plates were incubated at room temperature for 30 min, after which the plates were washed with 1% acetic acid to remove excess dye. The plates were air dried and a light microscope was used to capture the images. For quantitative measurements, 100 μ L of 10 mM Tris base solution was added to each well to solubilized protein bound dye and the absorbance was measured at 565 nm. The cytotoxicity of drug-loaded nanocarriers towards MDA MB 231 and HEK 293T cell lines were evaluated by IC₅₀ (half maximal inhibitory concentration) value.

3. Characterization

The synthesized nanocarrier and its related systems were confirmed by some advanced characterizing techniques such as Raman (Research India, RIRMLP1519), Fourier transform infrared (FT-IR), field emission scanning electron microscopy (FESEM). Also, ImageJ software was used for morphological illustration of prepared materials. Thermogravimetric analysis (TGA) was performed from 30 °C to 600 °C at a heating rate of 10 °C min⁻¹ under N₂ atmosphere by using Thermo Gravimetric Analyzer TGA 4000, PerkinElmer. Thereafter, the attachment of drug over the synthesized nanocarrier was also confirm by the electrochemical study using Electrochemical workstation, Metrohm Autolab. The drug loading capacity, entrapment efficiency and *in vitro* drug release behavior were studied using by UV-vis spectroscopy. The biocompatibility and cellular toxicity of synthesized nanocarriers were investigated by using SRB assay.

4. Results and discussion

4.1 Raman spectra analysis

Raman spectroscopy is a non-destructive and precise analysis technique to identify and characterized different types of carbon materials and also provides information about the structural variations during chemical processes. The Fig. 1 shows the Raman spectra of GO, GO-PVP and GO-PVP-Fe₃O₄. The Raman spectra of GO exhibit two prominent peaks at 1366.5 cm⁻¹ and 1573.1 cm⁻¹. The peak at 1366.5 cm⁻¹ assign to the D-band or deformation band of GO which is due to the stretching vibration of sp³ C-atoms resulting from the conversion of sp² C-atoms of graphite to sp³ C-atoms of GO during the oxidation of graphite. The peak at 1573.1 cm⁻¹ represents the Gband of GO which is originating from the vibrations of sp² Catoms. In addition to D and G bands of GO, the Fig. 1(a) shows the 2D band at 2861.9 cm⁻¹ which represents purity, formation of graphene structure and number of layers present in GO.³⁷ The intensity ratio of 2D and G band *i.e.*, I_{2D}/I_{G} shows the number of sheets in GO. According to the Raman spectra of



Fig. 1 Raman spectra of (a) GO (b) GO-PVP and (c) GO-PVP-Fe₃O₄.

GO, the I_{2D}/I_{G} ratio is 0.48, representing the existence of more than two layers of GO.

The Raman spectra of GO–PVP also exhibit peaks at 1372.9 cm⁻¹, 1583.0 cm⁻¹ and 2887.4 cm⁻¹ which are respectively assign to D-band, G-band and 2D-band (Fig. 1(b)). The intensity ratio of two characteristic band D and G *i.e.*, I_D/I_G ratio, determines the degree of disorder present in graphene sheet. The I_D/I_G ratio for GO and GO–PVP are 0.96 and 0.99 respectively. This increase in the intensity ratio from 0.96 to 0.99, resulting from the transformation of sp² hybridized indicating the successful grafting of PVP carbon to sp³ C-atoms after the functionalization of GO with PVP, on GO surface. Fig. 1(c) shows the Raman spectra of GO–PVP–Fe₃O₄ with disrupted of D, G and 2D bands and also exhibit slightly increased I_D/I_G ratio up to 1.10, which may be due to the structural distortions induced by Fe₃O₄ on GO–PVP surface.^{38,39}

4.2 FTIR spectra analysis

FTIR spectroscopy is a technique to confirms the formation of new bonds and presence of different functional groups in the compound. Within a certain range of wavenumber or frequency, each functional group vibrate with a particular frequency which is depends upon the geometry, relative mass of

atom and bonding force constant. Therefore, different chemical functional groups will vibrate at different frequencies. The Fig. 2 shows the FTIR spectra of GO, GO-PVP and GO-PVP- Fe_3O_4 nanocomposite which are performed at 400-4000 cm⁻¹ wavenumber range. The FT-IR spectra of GO exhibit a broad and intense absorption peak at 3224.34 cm⁻¹ which originates from the stretching vibration of O-H. This broad peak is a characteristic peak of hydroxyl (-OH) group. The absorption peaks at 1712.69 cm⁻¹ and 1620.62 cm⁻¹ are respectively assigned to the stretching vibration of C=O of carboxyl group and aromatic stretching vibration of C=C bond (originating from the graphite domain which was not undergo complete oxidation). Absorptions at 1224.4 cm⁻¹ and 1052.52 cm⁻¹ are respectively corresponds to the C-O-C (epoxy) and C-O (alkoxy) stretching vibrations. The presence of these absorption peaks indicated that the GO nanosheets containing abundant oxygenated functional groups were synthesized successfully.

In FT-IR spectra of GO–PVP, several new and intense peaks were appeared in addition to the absorption peaks in the spectra of GO due to the functionalization of GO with PVP. The absorption peak at 3330.41 cm⁻¹ is corresponds to the stretching vibration of N–H bond of secondary amine group. Additionally, the absorption peak at 2925.76 cm⁻¹ and 2850.03 cm⁻¹ appeared as a sharp doublet, which were



Fig. 2 FTIR spectra of (a) GO (b) GO-PVP and (c) GO-PVP-Fe₃O₄.

respectively due to the asymmetric and symmetric methylene $(-CH_2-)$ stretching. The absorption peaks at 1623.36 cm⁻¹, 1568.40 cm⁻¹ and 1435 cm⁻¹ are due to the characteristic stretching vibration of C=C bond, bending vibration of N-H and O-H bond respectively. The FTIR spectra of GO-PVP also exhibit an absorption peak at 1238.80 cm⁻¹ which assigned to the C-O stretching vibration of ester functional group which is formed during the functionalization. Generally, the validation of successful functionalization was done with the help of FTIR analysis. In the FTIR spectra of GO-PVP, the broad absorption peak of -OH group which is appeared around 3224 cm^{-1} in case of GO was completely disappeared after the functionalization with PVP. This reflect that the hydroxyl groups of GO may be involved in the formation of new bonds during the functionalization. Also, an additional peak was appeared around 1239 cm⁻¹ due to the formation of new C-O bond of ester functional group. Thus, based on the above results, we can conclude that -OH groups of the GO involve in the formation of ester during the functionalization with PVP. This confirms the successful functionalization of GO with PVP.

FT-IR analysis can also confirm the successful attachment of Fe_3O_4 nanoparticles onto GO nanosheet by the presence of absorption peak at 558.25 cm⁻¹. This peak corresponds to the stretching vibration of Fe–O and represents the formation of the coordination bond (C–O–Fe) between Fe_3O_4 nanoparticles and COO⁻ of GO. Moreover, the two new absorption peaks at 1484.3 cm⁻¹ and 1356.4 cm⁻¹ demonstrate the existence of interaction of Fe_3O_4 nanoparticles with hydroxyl and carbonyl groups of GO.⁴⁰

4.3 SEM-EDX analysis

The surface morphology and elemental composition of GO, GO– PVP and GO–PVP–Fe₃O₄ materials were characterized by SEM-EDX and ImageJ software. The Fig. 3(a) is the SEM image of GO which shows scrambled and sheets like structure. The sheets are look somewhat thicker on the edges which is due to



Fig. 3 (a) SEM image of GO, (b) Hill stack plot of GO and (c) 3D surface morphology of GO.

Paper

presence of oxygenating groups in GO. The Fig. 3(b) and (c) represent the hill stack profile and 3D surface morphology of GO respectively which shows uneven hills, curvy and thick corner of the sheet as well as suggesting the wrinkled sheet like morphology of GO, shows the good agreements with SEM image.

Also, SEM image of polymer grafted GO in Fig. 4(a) suggested that the polymer is very well grafted over the GO sheets which increase the thickness of sheets. The EDX spectrum of polymer grafted GO in Fig. 4(b) shows the major constituent elements such as C, N and O in 70.51%, 18.49% and 11.00%, respectively, which confirmed the successful functionalization GO with PVP. The Fig. 4(c) and (d) shows the hill stack plot and 3D surface morphology of GO–PVP, respectively. The hill stack plot shows the higher thickness and wider spike like structures in compared to GO, confirm the successful grafting of polymer over the GO surface. Further, same kind of conclusion can be drawn with 3D surface morphology of GO–PVP which confirm the wider spike and thicker sheet like structure.

The SEM image of GO–PVP–Fe₃O₄ nanocomposite in Fig. 5(a) exhibited a rough surface along with a good distribution of Fe₃O₄ magnetic nanoparticles onto polymer grafted GO sheets. The successful attachment Fe_3O_4 magnetic

nanoparticles on GO sheet was confirmed by the EDX analysis in Fig. 5(b) which indicated the presence of element Fe (34.50%) along with other constituent elements such as C, O and N in 41.00%, 22.27% and 2.23%, respectively. The Fig. 5(c) and (d) represent the hill stack view and 3D surface morphology of GO– PVP–Fe₃O₄, respectively. These figures also show external surface morphology of GO–PVP–Fe₃O₄. The hill stack plot indicates the somewhat spike like structure and roughness of GO–PVP–Fe₃O₄. This type of structure also confirmed by the 3D surface morphology of GO–PVP–Fe₃O₄ in which broader hump like assembly are observed.

4.4 Thermogravimetric analysis (TGA)

TGA is a characterizing technique for determining the quantity and change in a mass of a material as a function of temperature or time under controlled atmosphere.⁴¹ TGA thermograms of synthesized materials were recorded in an inert nitrogen atmosphere and the results are shown in Fig. 6. From TGA spectra of GO, it is clearly observed that GO is thermally not stable and shows three stages of weight losses. The initial weight loss was observed at temperatures below 100 °C, which is due to the evaporation of adsorbed water molecules in π stacked structure of GO. The second weight loss was occurred



Fig. 4 (a) SEM image of GO-PVP, (b) EDX spectra of GO-PVP, (c) Hill stack plot of GO-PVP and (d) 3D surface morphology of GO-PVP.



Fig. 5 (a) SEM image of GO-PVP-Fe₃O₄, (b) EDX spectra of GO-PVP-Fe₃O₄ (c) Hill stack plot of GO-PVP-Fe₃O₄ and (d) 3D surface morphology of GO-PVP-Fe₃O₄.



Fig. 6 TGA curves of GO, GO–PVP, PVP, GO–PVP–Fe $_3O_4$ and Fe $_3O_4$.

around 190 °C due to decomposition of labile oxidative functional groups. Finally, the third gradual weight loss was observed in the range of 250–600 °C which is attributed to the ignition of carbon framework. The TGA curve of GO–PVP clearly

shows that the thermal stability of GO was significantly improved after the functionalization with PVP. At 600 °C, the TGA data for GO–PVP showed 83.45% weight loss, whereas GO and pure PVP showed weight losses of 67.56% and 97.41%, respectively. As a result, we can estimate that the GO–PVP composite has around 46.77% GO and 53.23% PVP. The TGA curve of Fe₃O₄ and GO–PVP–Fe₃O₄ showed about 9.44% and 28.53% weight loss over the temperature ranging from 30 to 600 °C. The above TGA data revealed that the GO–PVP–Fe₃O₄ composite has about 25.79% GO–PVP and 74.21% Fe₃O₄. Therefore, the synthesized nanocarrier GO–PVP–Fe₃O₄ showed excellent thermal stability due to the inorganic nature of Fe₃O₄ nanoparticles in the nanocomposite.

4.5 HR-TEM analysis

The morphologies of as-prepared nanocomposites as well as the surface functionalization of GO with PVP was further investigated by HR-TEM analysis and the results are shown in Fig. 7. The wrinkled sheet like morphology of GO was clearly shown in Fig. 7(a), reflecting the successful synthesis of GO by the exfoliation of graphite powder using modified Hummer's method.²¹ The Fig. 7(b) shows the TEM image of GO–PVP, which suggested



Fig. 7 TEM images of (a) GO and (b) GO-PVP.

that the surface of GO has been covered by the polymer PVP and thus, the edges of GO–PVP become relatively coarse.¹⁷ Also, the thickness of GO sheets was increased after the functionalization with PVP, as seen in Fig. 7(b).

4.6 Drug loading

The loaded amount of drug as well as the entrapment efficiency of drug onto the synthesized nanocarrier are determined by using UV-vis spectroscopy. Fig. 8(a) and (b) shows the UV-vis spectra of GO, GO–PVP, GO–PVP–Fe₃O₄ and GO–PVP–Fe₃O₄– QSR. A band appeared at 225 nm in Fig. 8(a) due to the π – π * transitions of the aromatic C==C bond which is a significant peak for GO. In Fig. 8(b-1), a sharp rise around 280 nm confirms the functionalization of GO with PVP. In Fig. 8(b-2), the shift from 280 to 288 nm for GO–PVP attributed to the conjugation of Fe₃O₄ on the surface of GO–PVP. Also, a broad absorption band around 330–470 nm which confirms the presence of Fe₃O₄ in the synthesized nanocarrier. The absorption band appeared at 330 nm confirms the synthesis of nanosized Fe₃O₄ particles.⁴² The sharp UV-vis peak at around ~380 nm assigned to the QSR molecule which was identified in the UV-vis spectra of GO–PVP- Fe_3O_4 -QSR, as shown in Fig. 8(b-3) which confirms the successful loading of QSR onto the GO-PVP- Fe_3O_4 .

QSR is a hydrophobic anticancer drug, which commonly used for chemotherapy and was selected for studying the ability of GO-PVP-Fe₃O₄ as an anticancer drug carrier. QSR was loaded over the GO-PVP-Fe₃O₄ surface by simple mixing and sonication methods through hydrophobic interactions and π - π stacking between QSR and GO-PVP-Fe₃O₄. The QSR loading capacity of GO-PVP-Fe3O4 hybrid was determined by UV-vis spectrum at 380 nm, which was evaluated by the difference between the concentration of QSR in original solution (before loading) and supernatant solution (after loading). The QSR loading capacity of GO-PVP-Fe₃O₄ is as higher as 1.69 mg mg⁻¹. Further, the entrapment efficiency was found to be 84.8%. The loading capacity of QSR on GO-PVP is only about 0.14 mg mg⁻¹ as previously reported.²¹ On the basis of these results, we can conclude that the grafting of Fe₃O₄ on GO-PVP surface can effectively improve the QSR loading capacity of GO-PVP. Therefore, GO-PVP-Fe₃O₄ can be consider as the excellent nanocarrier with higher drug loading capacity. Further, our developed nanocarrier exhibit the excellent drug loading



Fig. 8 UV-vis spectra of (a) GO, (b-1) GO-PVP, (b-2) GO-PVP-Fe₃O₄ and (b-3) GO-PVP-Fe₃O₄-QSR.



Fig. 9 Cyclic voltammogram of the GO-PVP-Fe₃O₄, QSR and GO-PVP-Fe₃O₄-QSR modified GCE in 0.1 M PBS (pH 7.4) at the scan rates of (a) 20, (b) 50, (c) 75 and (d) 100 mV s⁻¹.

capacity in compared to other drug carriers, like as liposomes,⁴³ polymer micelles,⁴⁴ hydrogel microparticles,⁴⁵ where the loading capacity showed lower than of 1 mg mg⁻¹.²⁷

voltammogram at higher scan rates as shown in Fig. 9(b)–(d). All these figures revealed that as we increase the scan rate, reduced the diffusion rate of ions into the electrode and increase ion transport results higher peak current was observed. Therefore,

4.7 Electrochemical analysis

Electrochemical analysis was done for identification of attachment of QSR over GO–PVP–Fe₃O₄ nanocarrier. For this, we have performed the CV analysis under the voltage range of -1 to 1 V at different scan rates of 20 mV s⁻¹, 50 mV s⁻¹, 75 mV s⁻¹ and 100 mV s⁻¹ for GO–PVP–Fe₃O₄, QSR and GO–PVP–Fe₃O₄–QSR in 0.1 M PBS (pH 7.4) (Fig. 9).

The Fig. 9(a) shows the good cyclic reversibility for GO–PVP– Fe₃O₄, QSR and GO–PVP–Fe₃O₄–QSR under the performed voltage range. If we compared cyclic behavior of all three, we can see that the GO–PVP–Fe₃O₄ does not shows any prominent redox peak (oxidation and reduction peaks) but QSR shows a clear oxidation and reduction peak in the cyclic voltammogram. Further, after loading of QSR over GO–PVP–Fe₃O₄ nanocarrier based cyclic voltammogram also shows the prominent oxidation and reduction peaks of QSR at same range. This kind of behavior confirm the loading of QSR over GO–PVP–Fe₃O₄ nanocarrier *via* π – π interaction which help to facilitate the electron transport. Such behavior also observed in all cyclic



Fig. 10 Release profile of QSR from $GO-PVP-Fe_3O_4$ at pH 4 and 7.4.



Scheme 3 Detailed mechanism of pH responsive release of QSR from synthesized nanocarrier at acidic pH condition.

according to the above results we can conclude that the successful attachment of QSR over GO–PVP–Fe $_3O_4$ nanocarrier.

4.8 pH-responsive drug release behavior

To evaluate the release performance of the nanocarrier, *in vitro* release study was performed at two different pH conditions, pH 4 and 7.4, which shown in Fig. 10. The release of QSR from GO–PVP–Fe₃O₄ nanocarrier was found to be very slow at normal physiological condition and only about 15.76% of the total

bound QSR was released for 72 hours under normal physiological condition (pH 7.4). However, in acidic condition (pH 4), the release of QSR was found to be very quick at the early stages and after 12 hours, the rate of release gradually decreases. Finally, 35.40% of the total loaded QSR was released from the nanocarrier in 72 hours at pH 4. This represents the pHresponsive drug release behavior of synthesized nanocarrier.

This may be because of the stronger hydrogen bonding interaction between drug and nanocarrier under normal



Fig. 11 (a) Cell viability of non-tumorigenic HEK 293T cells with various concentrations of GO, GO–PVP, GO–PVP–Fe₃O₄, GO–PVP–Fe₃O₄–QSR and QSR, and (b) cell viability of human breast cancer MDA MB 231 cells with various concentrations of GO, GO–PVP, GO–PVP–Fe₃O₄, GO–PVP–Fe₃O₄–QSR and QSR.

physiological condition in comparison to the acidic condition, resulting in a slower release rate in normal physiological condition. Generally, tumor cells have acidic lysosomes. As expected for an ideal anticancer drug carrier, the synthesized nanocarrier (GO–PVP–Fe₃O₄) initially taken up to the cancer cell *via* endocytosis and finally the drug delivered at cancer cells. So, at lysosomal acidic pH less than 5.5, there is a weakening of hydrogen bonding between QSR and GO–PVP–Fe₃O₄ due to the electrostatic repulsion between the positively charged moieties (protonation occur at acidic pH), resulting larger desired release of QSR (Scheme 3). Considering the different releasing behaviors of QSR from GO–PVP–Fe₃O₄ at different pH conditions, this synthesized nanocarrier can be consider as a potential carrier for efficient release of drug.¹²

4.9 Evaluation of *in vitro* cytotoxicity of QSR loaded nanocarrier against breast cancer cells

The *in vitro* cytotoxicity effect of GO, GO–PVP, GO–PVP–Fe₃O₄ and GO–PVP–Fe₃O₄–QSR were studied in non-tumorigenic HEK 293T as well as human breast cancer MDA MB 231 cell lines. These cell lines were exposed with different concentrations (0, 10, 20, 30 and 50 μ g mL⁻¹) of GO, GO–PVP, GO–PVP–Fe₃O₄, GO– PVP–Fe₃O₄–QSR and QSR. *In vitro* cell viability of both cell lines were shown in Fig. 11. In Fig. 11(a), GO–PVP–Fe₃O₄ treated HEK 293T cells reveal no significant cytotoxicity at high concentration of 50 µg mL⁻¹. In Fig. 11(b), QSR-loaded GO– PVP–Fe₃O₄ shows excellent cytotoxicity against human breast cancer MDA MB 231 cells with around 28% cell viability at 50 µg mL⁻¹. Cell survival rate (%) = $(a - c)/(b - c) \times 100$ (a =absorbance at each concentration of the tested sample, b =absorbance at 0 µg mL⁻¹ of tested sample, and c = absorbance of the blank).

In addition, GO–PVP–Fe₃O₄–QSR exhibited IC₅₀ value in MDA MB 231 cells of 24.20 μ g mL⁻¹, whereas that of QSR in DMSO is 49.78 μ g mL⁻¹, suggesting that GO–PVP–Fe₃O₄–QSR has significant cytotoxic effects than free QSR against MDA MB 231 cells at the above-mentioned concentrations after treatment of 48 hours. These results indicate that GO–PVP–Fe₃O₄ nano-carrier could help to facilitate the delivery of QSR and hence, improve the cellular uptake of the drug. Further, the representative phase contrast microscopic images were captured at various concentrations of synthesized nanocarrier (with and without drug) to investigate the morphological changes of the cells which shown in Fig. 12.

With careful observation, we found that there is no significant cytotoxicity (>80% cell viability) observed for the GO-based nanocarriers at a concentration of 30 μ g mL⁻¹ for HEK 293T cells (Fig. 12), which indicates the minimal cytotoxicity and favorable biocompatibility of GO-based nanocarriers. However, when MDA MB 231 cells were treated with drug loaded GO-



Fig. 12 Phase contrast microscopic images of HEK 293T and MDA MB 231 cells after treatment with GO, GO–PVP, GO–PVP–Fe₃O₄, GO–FVP, GO–FVP,

based nanocarriers for 48 hours, a significant decrease in cell viability was observed. Therefore, it is concluded that GO–PVP– Fe_3O_4 could be a promising candidate for efficient delivery of QSR with considerable cytotoxicity towards the selected cancer cells.

5. Conclusion

In summary, we have successfully synthesized biocompatible and pH responsive magnetic nanocarrier GO–PVP–Fe₃O₄ for the efficient delivery of anticancer drug quercetin (QSR). GO–PVP– Fe₃O₄ could form stable complexes with QSR through noncovalent interactions and shows high drug loading capacity up to 1.69 mg mg⁻¹. We have also shown that in comparison to the free QSR alone, GO–PVP–Fe₃O₄–QSR exhibited higher cytotoxic effects to the human breast cancer MDA MB 231 cells at the various concentrations. Overall, our results highlight that polymer grafted magnetic graphene oxide could be a smart pH responsive nanocarrier based drug delivery platform for the efficient and controlled release of anticancer drugs.

Author contributions

Monika Matiyani: conceptualization, investigation, methodology, experimental and writing – original draft. Anita Rana: analysis and writing, Mintu Pal: experimental, review and editing. Nanda Gopal Sahoo: co-ordinated overall work, review and editing.

Conflicts of interest

We declare that we have no conflict of interest.

Acknowledgements

Authors acknowledge the financial support from Council of Scientific and Industrial Research (CSIR) (File No. 09/428(0079)/ 2018-EMR-I), New Delhi, India, National Mission on Himalayan Studies, GBPHIED (Ref. No. GBPNI/NMHS-2019-20/MG), Kosi-Katarmal, Almora, Uttarakhand, India and DST-FIST (Sanction No. SR/FST/CSI-262/2014(C)), New Delhi, India.

References

- 1 P. Kumari, B. Ghosh and S. Biswas, *J. Drug Targeting*, 2016, 24, 179–191.
- 2 Z. Yang, D. Gao, Z. Cao, C. Zhang, D. Cheng, J. Liu and X. Shuai, *Biomater. Sci.*, 2015, **3**, 1035–1049.
- 3 M. E. N. Ribeiro, İ. G. Vieira, I. M. Cavalcante, N. M. Ricardo,
 D. Attwood, S. G. Yeates and C. Booth, *Int. J. Pharm.*, 2009,
 378, 211–214.
- 4 K. A. Youdim, B. Shukitt-Hale and J. A. Joseph, *Free Radicals Biol. Med.*, 2004, **37**, 1683–1693.
- 5 R. T. Magar and J. K. Sohng, *J. Microbiol. Biotechnol.*, 2020, **30**, 11–20.

- 6 Y. Qi, P. Yi, T. He, X. Song, Y. Liu, Q. Li, J. Zheng, R. Song,
 C. Liu, Z. Zhang and W. Peng, *Colloids Surf.*, A, 2020, 602, 125058.
- 7 J. H. Jiang, J. Pi, H. Jin and J. Y. Cai, Artif. Cells, Nanomed., Biotechnol., 2018, 46, S297–S307.
- 8 J. C. Huang, Adv. Polym. Technol., 2002, 21, 299-313.
- 9 M. Ishigami, J. H. Chen, W. G. Cullen, M. S. Fuhrer and E. D. Williams, *Nano Lett.*, 2007, 7, 1643–1648.
- 10 J. Yan, Y. Zhang, S. Goler, P. Kim and A. Pinczuk, *Solid State Commun.*, 2007, **143**, 39–43.
- 11 A. K. Mishra and G. Roy, Int. J. Sci. Res., 2012, 3, 378-381.
- 12 X. Yang, Y. Wang, X. Huang, Y. Ma, Y. Huang, R. Yang, H. Duan and Y. Chen, *J. Mater. Chem.*, 2011, 21, 3448–3454.
- 13 M. Kakran, N. G. Sahoo, H. Bao, Y. Pan and L. Li, *Curr. Med. Chem.*, 2011, **18**, 4503–4512.
- 14 Y. Wang and X. Gong, Adv. Mater. Interfaces, 2017, 4, 1700190.
- 15 L. Zhong and X. Gong, Soft Matter, 2019, 15, 9500-9506.
- 16 Y. Liu, D. Yu, C. Zeng, Z. Miao and L. Dai, *Langmuir*, 2010, **26**, 6158–6160.
- 17 N. Karki, H. Tiwari, M. Pal, A. Chaurasia, R. Bal, P. Joshi and N. G. Sahoo, *Colloids Surf.*, *B*, 2018, **169**, 265–272.
- 18 N. G. Sahoo, H. Bao, Y. Pan, M. Pal, M. Kakran, H. K. F. Cheng, L. Li and L. P. Tan, *Chem. Commun.*, 2011, 47, 5235–5237.
- 19 Z. Liu, J. T. Robinson, X. Sun and H. Dai, J. Am. Chem. Soc., 2008, 130, 10876–10877.
- 20 L. Zhang, Z. Lu, Q. Zhao, J. Huang, H. Shen and Z. Zhang, *Small*, 2011, 7, 460–464.
- 21 H. Tiwari, N. Karki, M. Pal, S. Basak, R. K. Verma, R. Bal, N. D. Kandpal, G. Bisht and N. G. Sahoo, *Colloids Surf.*, *B*, 2019, **178**, 452–459.
- 22 Y. Pan, H. Bao, N. G. Sahoo, T. Wu and L. Li, Adv. Funct. Mater., 2011, 21, 2754–2763.
- 23 H. Bao, Y. Pan, Y. Ping, N. G. Sahoo, T. Wu, L. Li, J. Li and L. H. Gan, *Small*, 2011, 7, 1569–1578.
- 24 N. S. Chaudhari, A. P. Pandey, P. O. Patil, A. R. Tekade,
 S. B. Bari and P. K. Deshmukh, *Mater. Sci. Eng., C*, 2014, 37, 278–285.
- 25 X. Yang, Y. Chen, R. Yuan, G. Chen, E. Blanco, J. Gao and X. Shuai, *Polymer*, 2008, **49**, 3477–3485.
- 26 J. Huang, X. Zhong, L. Wang, L. Yang and H. Mao, *Theranostics*, 2012, 2, 86–102.
- 27 X. Yang, X. Zhang, Y. Ma, Y. Huang, Y. Wang and Y. Chen, *J. Mater. Chem.*, 2009, **19**, 2710–2714.
- 28 G. Xie, P. Xi, H. Liu, F. Chen, L. Huang, Y. Shi, F. Hou, Z. Zeng, C. Shao and J. Wang, *J. Mater. Chem.*, 2012, 22, 1033–1039.
- 29 P. S. Teo, H. N. Lim, N. M. Huang, C. H. Chia and I. Harrison, *Ceram. Int.*, 2012, **38**, 6411–6416.
- 30 Q. Zhang, B. Wu, R. Song, H. Song, J. Zhang and X. Hu, *Tribol. Int.*, 2020, **141**, 105952.
- 31 W. S. Hummers and R. E. Offeman, *J. Am. Chem. Soc.*, 1958, **80**, 1339.
- 32 H. K. F. Cheng, N. G. Sahoo, Y. P. Tan, Y. Pan, H. Bao, L. Li, S. W. Chan and J. Zhao, *ACS Appl. Mater. Interfaces*, 2012, 4, 2387–2394.

- 33 F. Trusell, Talanta, 1966, 13, 1043-1045.
- 34 Y. A. Neolaka, Y. Lawa, J. N. Naat, A. A. Riwu, M. Iqbal, H. Darmokoesoemo and H. S. Kusuma, *J. Mater. Res. Technol.*, 2020, 9, 6544–6556.
- 35 N. Hazhir, F. Chekin, J. B. Raoof and S. Fathi, *RSC Adv.*, 2019, 9, 30729–30735.
- 36 V. Vichai and K. Kirtikara, Nat. Protoc., 2006, 1, 1112.
- 37 M. Karakoti, R. Jangra, S. Pandey, P. S. Dhapola, S. Dhali,
 S. Mahendia, P. K. Singh and N. G. Sahoo, *High Perform. Polym.*, 2020, 32, 175–182.
- 38 K. Vinothini, N. K. Rajendran, M. Rajan, A. Ramu, N. Marraiki and A. M. Elgorban, *New J. Chem.*, 2020, 44, 5265–5277.
- 39 A. S. K. Kumar and S. J. Jiang, J. Mol. Liq., 2017, 237, 387–401.

- 40 N. Danesh, M. Hosseini, M. Ghorbani and A. Marjani, *Synth. Met.*, 2016, **220**, 508–523.
- 41 H. K. F. Cheng, N. G. Sahoo, X. Lu and L. Li, *J. Therm. Anal. Calorim.*, 2012, **109**, 17–25.
- 42 A. Rajan, A. Khan, S. Asrar, H. Raza, R. K. Das and N. K. Sahu, *IET Nanobiotechnol.*, 2019, **13**, 682–687.
- 43 W. Sun, N. Zhang, A. Li, W. Zou and W. Xu, Int. J. Pharm., 2008, 353, 243–250.
- 44 Y. Chan, T. Wong, F. Byrne, M. Kavallaris and V. Bulmus, *Biomacromolecules*, 2008, **9**, 1826–1836.
- 45 F. Cavalieri, E. Chiessi, R. Villa, L. Vigano, N. Zaffaroni, M. F. Telling and G. Paradossi, *Biomacromolecules*, 2008, 9, 1967–1973.